Yarrow Bioscience Closes $172.5M Offering After Full Underwriter Option Exercise
YARW sits 79% above its 52-week low of $14.675.
Summary
Yarrow Bioscience closed its underwritten public offering, raising approximately $172.5 million in gross proceeds after the full exercise of the underwriters' option to purchase additional shares. The final share count of 6,634,615 represents an increase from the initially priced 5.77 million shares, reflecting strong demand. The offering was priced at $26.00 per share, a 4.6% discount to the last close before pricing. Proceeds will fund R&D for YB-101 and general corporate purposes. This follows the company's recent merger with VYNE Therapeutics and a Phase 2a/2b trial initiation for YB-101.
At the time of this announcement, YARW was trading at $26.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.1M. The 52-week trading range was $14.68 to $46.95. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.